TNF antagonists in the treatment of inflammatory bowel disease: Results of a survey of gastroenterologists in the French region of Lorraine

Gastroenterologie Clinique et Biologique

Volumn 33, Issue 1 PART 1, 2009, Pages 23-30

  Peyrin Biroulet, L ^a   Oussalah, A ^a,b   Boucekkine, T ^b   Bigard, M A ^a  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

^b CHU Mustapha   (Algeria)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIBIOTIC AGENT; AZATHIOPRINE; INFLIXIMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ANTIBIOTIC THERAPY; ARTICLE; CHEMOPROPHYLAXIS; CLINICAL ASSESSMENT; CLINICAL PRACTICE; CONSULTATION; CROHN DISEASE; DRUG DOSE INCREASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENTERITIS; HEALTH CARE PERSONNEL; HEALTH SURVEY; HUMAN; MEDICAL PRACTICE; PHYSICIAN; PRESCRIPTION; QUESTIONNAIRE; SKIN TEST; THERAPY DELAY; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION;

EID: 58249083793     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gcb.2008.07.012     Document Type: Article

References (19)

1. Peyrin-Biroulet L., Desreumaux P., Sandborn W.J., and Colombel J.F. Crohn's disease: beyond antagonists of tumour necrosis factor. Lancet 372 (2008) 67-81
2. Peyrin-Biroulet L., Deltenre P., de Suray N., Branche J., Sandborn W.J., and Colombel J.F. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 6 (2008) 644-653
3. Lichtenstein G.R., Yan S., Bala M., Blank M., and Sands B.E. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology 128 (2005) 862-869
4. Present D.H., Rutgeerts P., Targan S., Hanauer S.B., Mayer L., van Hogezand R.A., et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 340 (1999) 1398-1405
5. Sands B.E., Anderson F.H., Bernstein C.N., Chey W.Y., Feagan B.G., Fedorak R.N., et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 350 (2004) 876-885
6. Rutgeerts P., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.F., et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 126 (2004) 402-413
7. Rutgeerts P., Diamond R.H., Bala M., Olson A., Lichtenstein G.R., Bao W., et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc 63 (2006) 433-442
8. Hanauer S.B., Wagner C.L., Bala M., Mayer L., Travers S., Diamond R.H., et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2 (2004) 542-553
9. Hanauer S.B., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.F., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359 (2002) 1541-1549
10. Menachem Y., Avidan B., Lavy A., Lang A., Bardan E., Fidder H., et al. Increasing the infliximab dose is beneficial in Crohn's disease patients who responded to a lower dose and relapsed. Digestion 72 (2005) 124-128
11. Peyrin-Biroulet L. Anti-TNF et maladie de Crohn. Gastroenterol Clin Biol 32 (2008) 478-481
12. Kaplan G.G., Hur C., Korzenik J., and Sands B.E. Infliximab dose escalation vs initiation of adalimumab for loss of response in Crohn's disease: a cost-effectiveness analysis. Aliment Pharmacol Ther 26 (2007) 1509-1520
13. Hanauer S.B., Sandborn W.J., Rutgeerts P., Fedorak R.N., Lukas M., MacIntosh D., et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 130 (2006) 323-333
14. Sandborn W.J., Rutgeerts P., Enns R., Hanauer S.B., Colombel J.F., Panaccione R., et al. Adalimumab induction therapy for Crohn's disease previously treated with infliximab: a randomized trial. Ann Intern Med 146 (2007) 829-838
15. Van Assche G., Magdelaine-Beuzelin C., D'Haens G., Baert F., Noman M., Vermeire S., et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 134 (2008) 1861-1868
16. Lemann M., Mary J.Y., Duclos B., Veyrac M., Dupas J.L., Delchier J.C., et al. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology 130 (2006) 1054-1061
17. Costes L., Colombel J.F., Mary J.Y., Duclos B., Veyrac M., Dupas J.L., et al. Long-term follow-up of a cohort of steroid-dependent Crohn's disease patients included in a randomized trial evaluating short-term infliximab combined with azathioprine (abstract). Gastroenterology 134 (2008) A134
18. Mackey A.C., Green L., Liang L.C., Dinndorf P., and Avigan M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 44 (2007) 265-267
19. Schnitzler F., Fidder H., Ferrante M., Noman M., van Assche G., Hoffman I., et al. Long-term outcome of treatment with infliximab in 440 Crohn's disease patients: Results from a single center cohort (abstract). Gastroenterology 132 Suppl. 2 (2007) A145